Overview
The aim of this study is to examine the efficacy and adverse events in the following 3 groups in Japanese osteoporosis patients after 2-year-denosumab therapy:
SERM and eldecalcitol treatment for 24 months Bisphosphonates and eldecalcitol treatment for 24 months Eldecalcitol treatment for 24 months
Eligibility
Inclusion Criteria:
- osteoporosis patients
Exclusion Criteria:
- not osteoporosis patients who are allergic to the drugs, refused to do this research, or who are pregnant